eligibility_summary
Eligible: 18-70 with histologically confirmed pancreatic cancer for curative resection, measurable disease (RECIST 1.1), ECOG 0-1, sufficient CD3+ cells (>1x10^9), adequate blood counts, renal and liver function, contraception, negative pregnancy test if needed. Exclude: AIDS, HBsAg+, active infection, severe comorbidity, T-cell expansion <5x, pregnant/lactating, other trials, chronic pancreatitis/IgG4, planned splenectomy, malignancy (except in-situ cervix/NMSC or cured >=5y), transplant history, or other unsuitability.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06054308 (withdrawn) tested mesothelin-targeted CAR-T cells as neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma. Intervention: endoscopic ultrasound–guided intratumoral injection of third‑generation, gene‑modified autologous CAR-T cells (cellular immunotherapy). Mechanism: the CAR binds mesothelin (MSLN) on tumor cells, triggering T-cell activation via CD3ζ with dual co‑stimulatory domains, leading to cytotoxic killing (perforin/granzyme) and cytokine release to reduce tumor burden and improve R0 resection. Targets: mesothelin-expressing PDAC cells (~80% of PDAC). Pathways: MSLN–MUC16 (CA125) adhesion/invasion axis, tumor cell proliferation/migration, and CAR-mediated T-cell effector pathways. Delivery is local (EUS) to enhance intratumoral activity.